{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:43:55Z","timestamp":1790315035782,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Boehringer Ingelheim"},{"DOI":"10.13039\/501100009109","name":"Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boehringer Ingelheim"},{"DOI":"10.13039\/501100009109","name":"Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.ctrv.2018.05.002","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T12:51:52Z","timestamp":1525783912000},"page":"38-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Assessment of the risk of antiangiogenic agents before and after surgery"],"prefix":"10.1016","volume":"68","author":[{"given":"Christina E.","family":"Bailey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2018.05.002_b0005","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2018.05.002_b0010","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2018.05.002_b0015","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2018.05.002_b0020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(09)70341-9","article-title":"Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care","volume":"11","author":"Bose","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0025","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jss.2008.04.023","article-title":"The role of vascular endothelial growth factor in wound healing","volume":"153","author":"Bao","year":"2009","journal-title":"J Surg Res"},{"key":"10.1016\/j.ctrv.2018.05.002_b0030","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0035","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.vascn.2007.08.002","article-title":"Development of a method for the evaluation of wound tensile strength in cynomolgus macaques","volume":"57","author":"Cornacoff","year":"2008","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.ctrv.2018.05.002_b0040","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/neuonc\/nor223","article-title":"Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors","volume":"14","author":"Armstrong","year":"2012","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0045","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3748\/wjg.v19.i5.761","article-title":"Preoperative administration of bevacizumab is safe for patients with colorectal liver metastases","volume":"19","author":"Li","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0050","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11605-012-2108-y","article-title":"Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases","volume":"17","author":"Lubezky","year":"2013","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.ctrv.2018.05.002_b0055","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1634\/theoncologist.2013-0107","article-title":"Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials","volume":"18","author":"Hurwitz","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2018.05.002_b0060","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1200\/JCO.2009.21.9220","article-title":"Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer","volume":"27","author":"Allegra","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0065","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.20301","article-title":"Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab","volume":"91","author":"Scappaticci","year":"2005","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0070","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1634\/theoncologist.2009-0071","article-title":"Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study","volume":"14","author":"Kozloff","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2018.05.002_b0075","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ejca.2012.02.052","article-title":"Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study","volume":"48","author":"Kabbinavar","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2018.05.002_b0080","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/jso.21598","article-title":"The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection","volume":"102","author":"Cheon","year":"2010","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0085","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1200\/JCO.2012.42.4044","article-title":"Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10","volume":"30","author":"McCahill","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0090","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.3748\/wjg.v21.i16.5072","article-title":"Value of bevacizumab in treatment of colorectal cancer: a meta-analysis","volume":"21","author":"Qu","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0095","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s40261-013-0125-6","article-title":"Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials","volume":"33","author":"Dai","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ctrv.2018.05.002_b0100","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ejca.2011.11.021","article-title":"Safety of bevacizumab in metastatic breast cancer patients undergoing surgery","volume":"48","author":"Cortes","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2018.05.002_b0105","doi-asserted-by":"crossref","unstructured":"Gerber B, von MG, Eidtmann H, Rezai M, Fasching P, Tesch H, et al. Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44). Ann Surg Oncol 2014; 21:2517\u201324.","DOI":"10.1245\/s10434-014-3606-9"},{"key":"10.1016\/j.ctrv.2018.05.002_b0110","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1245\/s10434-010-1366-8","article-title":"Does neoadjuvant bevacizumab increase surgical complications in breast surgery?","volume":"18","author":"Golshan","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10549-013-2682-z","article-title":"Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction","volume":"141","author":"Kansal","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2018.05.002_b0120","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s00595-014-0912-6","article-title":"Impaired wound healing and expansion of a large ulcer after bevacizumab with paclitaxel for skin metastases from breast cancer: report of a case","volume":"45","author":"Kijima","year":"2015","journal-title":"Surg Today"},{"key":"10.1016\/j.ctrv.2018.05.002_b0125","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s00266-010-9535-5","article-title":"Impaired wound healing and bilateral mastectomy flap necrosis in a patient with locally advanced breast cancer after neoadjuvant Paclitaxel with bevacizumab","volume":"34","author":"Lazzati","year":"2010","journal-title":"Aesthetic Plast Surg"},{"key":"10.1016\/j.ctrv.2018.05.002_b0130","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11060-015-1868-0","article-title":"Wound healing complications in brain tumor patients on Bevacizumab","volume":"124","author":"Ladha","year":"2015","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0135","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1200\/JCO.2010.30.2729","article-title":"Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme","volume":"29","author":"Lai","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0140","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1158\/1078-0432.CCR-11-0120","article-title":"The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma","volume":"17","author":"Vredenburgh","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2018.05.002_b0145","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.3171\/2010.10.JNS101042","article-title":"Impact of bevacizumab chemotherapy on craniotomy wound healing","volume":"114","author":"Clark","year":"2011","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ctrv.2018.05.002_b0150","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1634\/theoncologist.2014-0330","article-title":"Practical management of bevacizumab-related toxicities in glioblastoma","volume":"20","author":"Brandes","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2018.05.002_b0155","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1200\/JCO.2008.21.3660","article-title":"Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma","volume":"27","author":"Jonasch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0160","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.juro.2008.03.047","article-title":"Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma","volume":"180","author":"Margulis","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0165","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.urology.2008.01.088","article-title":"Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy","volume":"72","author":"Amin","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.ctrv.2018.05.002_b0170","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.juro.2008.10.001","article-title":"Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma","volume":"181","author":"Thomas","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0175","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.2009.24.7759","article-title":"Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma","volume":"28","author":"Cowey","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0180","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.urolonc.2011.01.005","article-title":"Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC)","volume":"31","author":"Harshman","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0185","doi-asserted-by":"crossref","unstructured":"Finley DJ, Shen R, Rizvi A, Rusch VW, Kris MG. Operative outcomes using bevacizumab, docetaxel, and cisplatin as induction therapy in patients with operable lung cancer. Proc Am Soc Clin Oncol 2009; 27.","DOI":"10.1200\/jco.2009.27.15_suppl.7559"},{"key":"10.1016\/j.ctrv.2018.05.002_b0190","first-page":"2421","article-title":"Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials","volume":"9","author":"Lai","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ctrv.2018.05.002_b0195","first-page":"4743","article-title":"Wound complications after bevacizumab treatment in patients operated on for ovarian cancer","volume":"30","author":"Koskas","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2018.05.002_b0200","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2018.05.002_b0205","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2018.05.002_b0210","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0215","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0220","first-page":"2701","article-title":"Adverse events risk associated with angiogenesis inhibitors addition to therapy in ovarian cancer: a meta-analysis of randomized controlled trials","volume":"20","author":"Liang","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.ctrv.2018.05.002_b0225","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s12094-015-1293-z","article-title":"Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials","volume":"17","author":"Li","year":"2015","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0230","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jvir.2009.01.022","article-title":"Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy","volume":"20","author":"Zawacki","year":"2009","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0235","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/cncr.25573","article-title":"Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement","volume":"117","author":"Erinjeri","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2018.05.002_b0240","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1097\/CAD.0b013e328349c7bb","article-title":"Wound healing and catheter thrombosis after implantable venous access device placement in 266 breast cancers treated with bevacizumab therapy","volume":"22","author":"Kriegel","year":"2011","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ctrv.2018.05.002_b0245","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jso.20938","article-title":"\u201cSpontaneous,\u201d delayed colon and rectal anastomotic complications associated with bevacizumab therapy","volume":"97","author":"August","year":"2008","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0250","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.clinre.2011.04.011","article-title":"Anastomotic dehiscence during treatment with bevacizumab 5 years after colo-anal anastomosis with proposition for management without stopping chemotherapy","volume":"35","author":"Eveno","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0255","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.clon.2011.03.009","article-title":"Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer","volume":"23","author":"Garant","year":"2011","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ctrv.2018.05.002_b0260","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/SAP.0b013e3182583ee6","article-title":"Case report: management of persistent dural anastomotic dehiscence in a patient treated with bevacizumab","volume":"71","author":"Elstner","year":"2013","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.ctrv.2018.05.002_b0265","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.clineuro.2014.10.012","article-title":"Extremely late wound dehiscence following bevazicumab treatment in a long term survival glioblastoma patient","volume":"127","author":"Laviv","year":"2014","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.ctrv.2018.05.002_b0270","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jamcollsurg.2011.12.030","article-title":"Bevacizumab-associated fistula formation in postoperative colorectal cancer patients","volume":"214","author":"Ganapathi","year":"2012","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ctrv.2018.05.002_b0275","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00280-007-0664-8","article-title":"Clinical pharmacokinetics of bevacizumab in patients with solid tumors","volume":"62","author":"Lu","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0280","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s13193-011-0100-8","article-title":"Neo adjuvant treatment with targeted molecules for renal cell cancer in current clinical practise","volume":"3","author":"Pooleri","year":"2012","journal-title":"Indian J Surg Oncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0285","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.juro.2009.05.014","article-title":"Surgical resection of renal cell carcinoma after targeted therapy","volume":"182","author":"Thomas","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0290","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s40265-014-0302-9","article-title":"Bevacizumab: a review of its use in advanced cancer","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2018.05.002_b0295","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11912-012-0238-8","article-title":"Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers","volume":"14","author":"Abu-Hejleh","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ctrv.2018.05.002_b0300","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00228-014-1687-9","article-title":"Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups","volume":"70","author":"Qi","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0305","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40261-015-0355-x","article-title":"The impact of ramucirumab on survival in patients with advanced solid tumors: a systematic review and meta-analysis of randomized II\/III controlled trials","volume":"36","author":"Wang","year":"2016","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ctrv.2018.05.002_b0310","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1093\/annonc\/mdx514","article-title":"Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0315","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2146\/ajhp130143","article-title":"Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer","volume":"70","author":"Chung","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ctrv.2018.05.002_b0320","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.critrevonc.2015.02.007","article-title":"Bevacizumab increases the risk of infections in cancer patients: a systematic review and pooled analysis of 41 randomized controlled trials","volume":"94","author":"Qi","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0325","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/bcp.12758","article-title":"Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis","volume":"81","author":"Zhang","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0330","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40261-014-0174-5","article-title":"Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis","volume":"34","author":"Qi","year":"2014","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ctrv.2018.05.002_b0335","doi-asserted-by":"crossref","first-page":"e111839","DOI":"10.1371\/journal.pone.0111839","article-title":"Incidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis","volume":"9","author":"Peng","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2018.05.002_b0340","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ctrv.2017.07.006","article-title":"Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies","volume":"59","author":"Santoni","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2018.05.002_b0345","first-page":"460","article-title":"Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events","volume":"29","author":"Wu","year":"2011","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ctrv.2018.05.002_b0350","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1093\/annonc\/mdt292","article-title":"Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials","volume":"24","author":"Qi","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0355","doi-asserted-by":"crossref","first-page":"67661","DOI":"10.18632\/oncotarget.11813","article-title":"Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2018.05.002_b0360","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0365","unstructured":"AVASTIN\u00ae. (bevacizumab) solution for intravenous infusion [package insert]. South San Francisco, CA: Genentech, Inc.; 2015."},{"key":"10.1016\/j.ctrv.2018.05.002_b0370","unstructured":"European Medicines Agency. EPAR summary for the public. Avastin bevacizumab. Available at: <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000582\/WC500029260.pdf> [accessed]."},{"key":"10.1016\/j.ctrv.2018.05.002_b0375","unstructured":"CYRAMZA\u00ae. (ramucirumab) injection, for intravenous use [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015."},{"key":"10.1016\/j.ctrv.2018.05.002_b0380","unstructured":"STIVARGA\u00ae. (regorafenib) tablets, for oral use. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; 2015."},{"key":"10.1016\/j.ctrv.2018.05.002_b0385","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s12094-014-1212-8","article-title":"Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer","volume":"16","author":"Sastre","year":"2014","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0390","unstructured":"NEXAVAR\u00ae. (sorafenib) tablets, oral [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals; 2015."},{"key":"10.1016\/j.ctrv.2018.05.002_b0395","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2018.05.002_b0400","doi-asserted-by":"crossref","first-page":"e0120877","DOI":"10.1371\/journal.pone.0120877","article-title":"A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting","volume":"10","author":"Fishman","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2018.05.002_b0405","unstructured":"SUTENT\u00ae. (sunitinib malate) capsules, oral [package insert]. New York, NY: Pfizer Inc; 2011."},{"key":"10.1016\/j.ctrv.2018.05.002_b0410","unstructured":"OFEV\u00ae. (nintedanib) capsules, for oral use [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2016."},{"key":"10.1016\/j.ctrv.2018.05.002_b0415","unstructured":"European Medicines Agency. Ofev\u00ae capsules: summary of product characteristics; 2015."},{"key":"10.1016\/j.ctrv.2018.05.002_b0420","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.2147\/OTT.S78805","article-title":"Profile of nintedanib in the treatment of solid tumors: the evidence to date","volume":"8","author":"Awasthi","year":"2015","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ctrv.2018.05.002_b0425","unstructured":"VOTRIENT\u00ae. (pazopanib) tablets [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2012."},{"key":"10.1016\/j.ctrv.2018.05.002_b0430","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1756287215614236","article-title":"Pazopanib in the treatment of advanced renal cell carcinoma","volume":"8","author":"Cella","year":"2016","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.ctrv.2018.05.002_b0435","unstructured":"INLYTA\u00ae. (axitinib) tablets for oral administration [package insert]. New York, NY: Pfizer Labs; 2012."},{"key":"10.1016\/j.ctrv.2018.05.002_b0440","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/CMAR.S74202","article-title":"Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma","volume":"7","author":"Gunnarsson","year":"2015","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ctrv.2018.05.002_b0445","unstructured":"CAPRELSA\u00ae. (vandetanib) Tablets [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2013."},{"key":"10.1016\/j.ctrv.2018.05.002_b0450","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2146\/ajhp120253","article-title":"Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer","volume":"70","author":"Ton","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ctrv.2018.05.002_b0455","unstructured":"COMETRIQ\u2122. (cabozantinib) capsules, for oral use. South San Francisco, CA: Exelixis, Inc.; 2012."},{"key":"10.1016\/j.ctrv.2018.05.002_b0460","first-page":"395","article-title":"Cabozantinib for progressive metastatic medullary thyroid cancer: a review","volume":"10","author":"Colombo","year":"2014","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.ctrv.2018.05.002_b0465","unstructured":"LENVIMA\u00ae. (lenvatinib) capsules, for oral use. Woodcliff Lake, NJ: Eisai Inc.; 2015."},{"key":"10.1016\/j.ctrv.2018.05.002_b0470","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2018.05.002_b0475","unstructured":"ZALTRAP\u00ae. (ziv-aflibercept) injection for intravenous infusion [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2016."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737218300653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737218300653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T13:50:13Z","timestamp":1604238613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737218300653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":95,"alternative-id":["S0305737218300653"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2018.05.002","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of the risk of antiangiogenic agents before and after surgery","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2018.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}